Merck KGaA expands life science footprint with Bio-Techne acquisition

PARAGRAPH 1 --- On June 24, 2022, Germany's Merck KGaA announced a $11.3 billion acquisition of U.S.-based Bio-Techne Corp (NASDAQ:TECH), marking one of the year's largest pharma and life-sciences deals. Merck will pay $73 per share, a 36% premium to Bio-Techne's pre-announcement price.

PARAGRAPH 2 --- This acquisition drives a significant expansion of Merck's life science footprint, particularly in the U.S. Bio-Techne's products, including reagents, instruments, and bioprocessing tools, will bolster Merck's offerings in research and bioproduction. The deal is expected to close in Q1 2023, subject to regulatory approvals.

PARAGRAPH 3 --- Investors should watch for updates on the deal's progress, including regulatory clearances. Additionally, Merck's Q2 2022 earnings, slated for late July, may provide more insights into the strategic fit and integration plans for Bio-Techne. Lastly, Bio-Techne's stock price, currently around $70, will be key to monitor, as it could retest or surpass the $73 acquisition price.